Direct treatment comparison of DAbigatran and RIvaroxaban versus NAdroparin in the prevention of venous thromboembolism after total knee arthroplasty surgery: design of a randomised pilot study (DARINA)

Lucia van der Veen, Jos Jam van Raay, Carina L E Gerritsma-Bleeker, Nic Jgm Veeger, Marinus van Hulst, Lucia van der Veen, Jos Jam van Raay, Carina L E Gerritsma-Bleeker, Nic Jgm Veeger, Marinus van Hulst

Abstract

Introduction: Two novel agents, dabigatran and rivaroxaban, recently gained market authorisation for prevention of venous thromboembolism (VTE) after hip and knee arthroplasty. However, safety data of the new oral anticoagulants with a long-term use of 42 days are not available for total knee arthroplasty (TKA). Furthermore, there are no clinical trials comparing dabigatran and/or rivaroxaban with nadroparin, which is used in most Dutch departments of orthopaedic surgery. Our aim is to compare the 42-day use of dabigatran and rivaroxaban versus nadroparin after TKA in a clinical explorative pilot study by assessing the incidence of major bleeding and clinically relevant non-major bleeding using a standardised model of bleeding definitions.

Methods and analysis: A randomised open-label pilot study was conducted. Patients ≥18 years and weighing more than 40 kg who were scheduled for a primary elective TKA were included. Patients were randomly assigned to three groups. Patients took either a daily oral dose of dabigatran etexilate 220 mg (n=50), 10 mg of oral rivaroxaban (n=50) or subcutaneous nadroparin 0.3 ml (n=50) for 42 days. The primary safety outcome measure was the incidence of bleeding events. Major bleeding events and clinically relevant non-major bleeding events were defined according to accepted guidelines. The secondary measures of this study were the occurrence of VTE, time until the bleeding event, compliance, duration of hospital stay, rehospitalisation, outpatient clinic visits and interventions following complications. Additionally, coagulation monitoring, knee flexion range of motion and Knee injury and Osteoarthritis Outcome Score were evaluated.

Dissemination: The results of this trial provided insight into the validity of design for an adequately powered multicentre study investigating the safety of the new oral anticoagulants compared with nadroparin, an anticoagulant applied for prevention of VTE after knee arthroplasty in the Dutch situation.

Trial registration number: ClinicalTrials.gov: NCT01431456.

References

    1. Warwick D, Friedman RJ, Agnelli G, et al. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br 2007;89:799–807
    1. White RH. The epidemiology of venous thromboembolism. Circulation 2003;10723 (Suppl 1):I4–8
    1. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001;119(1 Suppl):132S–75S
    1. Anderson FA, Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003;107(23 Suppl 1):I9–16
    1. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):381S–453S
    1. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776–86
    1. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009;373:1673–80
    1. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178–85
    1. Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;24:1–9
    1. Galanis T, Thomson L, Palladino M, et al. New oral anticoagulants. J Thromb Thrombolysis 2011;31:310–20
    1. Huisman MV, Quinlan DJ, Dahl OE, et al. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: results of separate pooled analyses of phase III multicenter randomized trials. Circ Cardiovasc Qual Outcomes 2010;3:652–60
    1. Friedman RJ, Dahl OE, Rosencher N, et al. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res 2010;126:175–82
    1. Toenders WGMCvz. CFH-rapport 08/16, dabigatran (Pradaxa®). College voor zorgverzekeringen, 23 June 2011
    1. Graaff van der MCvz. CFH-rapport 09/03, rivaroxaban (Xarelto®). 2011 (13) Nederlandse Orthopaedische vereniging. Richtlijn Diagnostiek en Behandeling van heup- en knieartrose. CBO 2007
    1. Nederlandse Orthopaedische Vereniging Richtlijn Diagnostiek en Behandeling van heup- en knieartrose. CBO 2007
    1. Ettema HB, Mulder MC, Nurmohamed MT, et al. Dutch orthopedic thromboprophylaxis: a 5-years follow-up survey. Acta Orhopaedica 2009;80:109–12
    1. White RH, Romano RS, Zhou H, et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthorplasty. Arch Intern Med 1998;158:1525–31
    1. Bergqvist D, Benoni G, Gjorgell O, et al. Low-molecular-weight-heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996;335:696–700
    1. Eriksson B, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thrormoembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370:949–56
    1. Eriksson B, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. NEJM 2008;358:26
    1. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2007;372:31–9
    1. ROCKET AF investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010;159:340–7
    1. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376:975–83
    1. Hull RD, Yusen RD, Bergqvist D. State-of-the-art review: assessing the safety profiles of new anticoagulants for major orthopaedic surgery thromboprophylaxis. Clin Appl Thromb Hemost 2009;15:377–88
    1. European Medicines Agency (EMEA) Guideline on clinical investigation of medicinal products for prophylaxis of high intra- and post-operative venous thromboembolic risk (CPMP/EWP/707/98). 15 November 2007
    1. Trkulja V, Kolundzic R. Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials. Croat Med J 2010;51:113–23
    1. Loke YK, Kwok CS. Dabigatran and rivaroxaban for prevention of venous thromboembolism—systematic review and adjusted indirect comparison. J Clin Pharm Ther 2011;36:111–24
    1. Groot de IB, Favejee MM, Reijman M, et al. The Dutch version of the Knee Injury and Osteoarthritis Outcome Score: a validation study. Health Qual Life Outcomes 2008;6:16.
    1. CBO richtlijn bloedtransfusie Kwaliteitsinstituut voor de Gezondheidszorg CBO. Guideline on clinical bloodtransfusions in the Netherlands, 2004.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe